Meeting
2023 ASCO Annual Meeting
Mechanisms of resistance to tyrosine kinase inhibitor treatments in patients with ROS1 fusion-positive non-small cell lung cancer.
Authors
Jialei Wang
Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
Jialei Wang , Xinmin Zhao , Xin Zhang , Hanlin Chen , Hairong Bao , Xianghua Wu , Huijie Wang , Hua Bao , Jiao Pang , Sha Wang , Haimeng Tang , Shiting Tang , Xue Wu , Yang Shao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9062)
DOI
10.1200/JCO.2023.41.16_suppl.9062
Abstract #
9062
Poster Bd #
50
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita
Poster
2022 ASCO Annual Meeting
Treatment patterns and outcomes in ALK or ROS1 altered NSCLC: An ATOMIC Registry Study.
First Author: Melina Elpi Marmarelis
Poster
2020 ASCO Virtual Scientific Program
Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer.
First Author: Jessica Jiyeong Lin
Poster
2023 ASCO Annual Meeting
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
First Author: Hongyun Zhao